Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 3/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070526 | 0.83 | CDK7 (0.38) | ADRA1DADRA1AADRA1BADRA2A | |
| SCHEMBL11919207 | 0.76 | KCNN3 (0.33) | — | |
| SCHEMBL12769217 | 0.73 | METAP2 (0.42) | THRB | |
| SCHEMBL15219297 | 0.73 | ALK (0.47) | ZAP70 | |
| SCHEMBL19526842 | 0.71 | PRKAB2 (0.38) | — | |
| SCHEMBL15214952 | 0.68 | CDK9 (0.41) | ADRA1DADRA1AADRA1BADRA2A | |
| SCHEMBL3024611 | 0.67 | MAPKAPK2 (0.50) | — | |
| SCHEMBL1070192 | 0.67 | CDK7 (0.38) | ADRA1DADRA1AADRA1BADRA2A | |
| SCHEMBL19527077 | 0.66 | KCNN3 (0.33) | — | |
| SCHEMBL12584676 | 0.64 | KCNN3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ADRA2C 3727/4885ADRA1D 3975/4885ADRA1A 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.